H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $81 from $80 and keeps a Buy rating on the shares. The company reported a “solid beat and raise quarter,” the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals price target raised to $95 from $81 at Citizens JMP
- Mirum Pharmaceuticals Reports Strong Q3 2025 Growth
- Mirum Pharmaceuticals: Strong Q3 Performance and Promising Pipeline Drive Buy Rating
- Mirum Pharmaceuticals reports Q3 EPS 5c, consensus (16c)
- Mirum Pharmaceuticals sees FY25 product sales of $500M-$510M, consensus $506.3M